Catherine Guly
University Hospitals Bristol NHS Foundation Trust
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Catherine Guly.
Survey of Ophthalmology | 2016
Madeleine J Hawkins; Andrew D. Dick; Richard W J Lee; Athimalaipet V Ramanan; Ester Carreño; Catherine Guly; Adam H Ross
Bilateral chronic anterior uveitis is an extra-articular feature of juvenile idiopathic arthritis. Although figures vary, uveitis occurs in approximately 11%-13% of patients with this disease and is most commonly associated with the female gender, oligoarthritis, and presence of antinuclear antibodies. The disease has an insidious onset and is often asymptomatic. Managing patients with juvenile idiopathic arthritis-associated uveitis remains challenging as the disease may prove to be refractory to traditional treatment regimens. Stepwise immunomodulatory therapy is indicated, with new biologic drugs being used last in cases of refractory uveitis. Small scale studies and practice have provided the evidence to undertake randomized control trials to evaluate the efficacy, safety, and cost-effectiveness of anti-tumor necrosis factor-α therapies, such as infliximab and adalimumab. These have demonstrated promising results, with further data awaited from ongoing trials for adalimumab (as SYCAMORE and ADJUVITE trials). Lower grade evidence is supporting the use of newer biologics such as rituximab, daclizumab, tocilizumab, and abatacept in those cases refractory to anti-tumor necrosis factor-α therapy.
The Journal of Rheumatology | 2014
Jessica A Little; Ethan S Sen; Helen Strike; Annie Hinchcliffe; Catherine Guly; Richard W J Lee; Andrew D. Dick; Athimalaipet V Ramanan
Objective. To assess the safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious childhood uveitis. Methods. Subjects were retrospectively selected from a database. Patients were included if they were diagnosed with chronic, noninfectious uveitis at 16 years of age or under and treated with triple immunosuppressive therapy for at least 6 months (following failure of a combination of 2 immunosuppressants). Patient demographics, diagnoses, duration of uveitis, drug dosages, active joint inflammation, and ophthalmologic data were recorded. Efficacy outcomes for triple therapy were recorded at 6 months. Results. Thirteen patients with bilateral uveitis were included. Using Standardized Uveitis Nomenclature (SUN) criteria, at 6 months only 11 eyes (42%) had a 2-step improvement in anterior chamber cell inflammation (n = 26). In addition, 2 patients required additional oral corticosteroid treatment. There were 4 significant infectious adverse events during a total of 21.9 patient-years (PY) on triple therapy (0.18 events per PY). Conclusion. In this group of children with refractory uveitis, addition of a third immunosuppressive agent did not confer substantial benefit in redressing ocular inflammation and was associated with significant infections in a minority of patients.
Acta Ophthalmologica | 2015
Ester Carreño; Catherine Guly; Michael Chilov; Annie Hinchcliffe; Juan I. Aróstegui; Richard W J Lee; Andrew D. Dick; Athimalaipet V Ramanan
To determine whether patients with juvenile systemic granulomatous disease (JSGD) (Blau syndrome) and uveitis have a characteristic ocular phenotype.
Archives of Disease in Childhood | 2014
Anna Catherine Kilonback; Catherine Guly; Jolanta Bernatoniene; Athimalaipet V Ramanan
A 9-year-old girl presented with loss of vision in the left eye. Three months prior to presentation, she experienced a viral-like illness with coryzal symptoms, headache, fever and loss of vision in the left eye. Her systemic symptoms improved spontaneously within days but the visual loss persisted. The patient did not present to secondary care until 3 months had passed. On presentation her visual acuity was 6/3.75 in the right eye and 3/60 in the left eye. She was …
Rheumatology | 2018
Lin Wang; Carlos D. Rose; Kevin Foley; Jordi Anton; Brigitte Bader-Meunier; Philippe Brissaud; Gaëlle Chédeville; Rolando Cimaz; Jorge Fernandez-Martin; Catherine Guly; E. Hachulla; Miroslav Harjacek; Friederike Mackensen; Rosa Merino; Consuelo Modesto; Antonio Naranjo Hernández; Christine Pajot; Athimalaipet V Ramanan; Akaluck Thatayatikom; Caroline Thomee; Sebastiaan J. Vastert; Bart Votta; John Bertin; Carine Wouters
Objective To identify biomarkers of articular and ocular disease activity in patients with Blau syndrome (BS). Methods Multiplex plasma protein arrays were performed in five BS patients and eight normal healthy volunteers (NHVs). Plasma S100A12 and S100A8/9 were subsequently measured by ELISA at baseline and 1-year follow-up in all patients from a prospective multicentre cohort study. CRP was measured using Meso Scale Discovery immunoassay. Active joint counts, standardization uveitis nomenclature for anterior uveitis cells and vitreous haze by Nussenblatt scale were the clinical parameters. Results Multiplex Luminex arrays identified S100A12 as the most significantly elevated protein in five selected BS vs eight NHVs and this was confirmed by ELISA on additional samples from the same five BS patients. In the patient cohort, S100A12 (n = 39) and S100A8/9 (n = 33) were significantly higher compared with NHVs (n = 44 for S100A12, n = 40 for S100A8/9) (P = 0.0000004 and P = 0.0003, respectively). Positive correlations between active joint counts and S100 levels were significant for S100A12 (P = 0.0008) and S100A8/9 (P = 0.015). CRP levels did not correlate with active joint count. Subgroup analysis showed significant association of S100 proteins with active arthritis (S100A12 P = 0.01, S100A8/9 P = 0.008). Active uveitis was not associated with increased S100 levels. Conclusion S100 proteins are biomarkers of articular disease activity in BS and potential outcome measures in future clinical trials. As secreted neutrophil and macrophage products, S100 proteins may reflect the burden of granulomatous tissue in BS.
Ophthalmic Surgery and Lasers | 2018
Inés Hernanz; Sarah Horton; Tomas R. Burke; Catherine Guly; Ester Carreño
Acute macular neuroretinopathy (AMN) is a rare disease, the etiology of which remains unclear. An ischemic event at the level of the deep capillary plexus has been proposed. The authors present three cases of AMN in the context of active systemic Behçets disease, with the support of multimodal imaging. All patients were known to have Behçets disease before the diagnosis of AMN. AMN was confirmed in all three cases on spectral domain optical coherence tomography (SD-OCT), near infrared reflectance and OCT angiography. Behçets disease is known to be a prothrombotic disease. The presentation of AMN in this context supports the presumed ischemic etiology of AMN. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:634-638.].
American Journal of Ophthalmology | 2017
Inge L. Sarens; Ingele Casteels; Jordi Anton; Brigitte Bader-Meunier; Philippe Brissaud; Gaëlle Chédeville; Rolando Cimaz; Andrew D. Dick; G Espada; Jorge Fernandez-Martin; Catherine Guly; Eric Hachulla; Miroslav Harjacek; Raju Khubchandani; Friederike Mackensen; Rosa Merino; Consuelo Modesto; Antonio Naranjo; Sheila Oliveira-Knupp; Seza Ozen; Christine Pajot; Athimalaipet V Ramanan; Ricardo Russo; Gordana Susic; Akaluck Thatayatikom; Caroline Thomee; Sebastiaan J. Vastert; John Bertin; Juan I. Aróstegui; Carlos D. Rose
Annals of the Rheumatic Diseases | 2018
Athimalaipet V Ramanan; Catherine Guly
Arthritis & Rheumatism | 2014
Ester Carreño; Catherine Guly; Michael Chilov; Annie Hinchcliffe; Juan I. Aróstegui; Richard W J Lee; Adrew D Dick; Athimalaipet V Ramanan
Pediatric Rheumatology | 2018
Megan Cann; Athimalaipet V Ramanan; Andrew Crawford; Andrew D. Dick; Sarah L. N. Clarke; Fatima Rashed; Catherine Guly